JP2013506696A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506696A5
JP2013506696A5 JP2012532388A JP2012532388A JP2013506696A5 JP 2013506696 A5 JP2013506696 A5 JP 2013506696A5 JP 2012532388 A JP2012532388 A JP 2012532388A JP 2012532388 A JP2012532388 A JP 2012532388A JP 2013506696 A5 JP2013506696 A5 JP 2013506696A5
Authority
JP
Japan
Prior art keywords
subject
medicament
peptide
heart failure
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012532388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/051329 external-priority patent/WO2011044044A1/en
Publication of JP2013506696A publication Critical patent/JP2013506696A/ja
Publication of JP2013506696A5 publication Critical patent/JP2013506696A5/ja
Pending legal-status Critical Current

Links

JP2012532388A 2009-10-05 2010-10-04 心不全の予防又は処置の方法 Pending JP2013506696A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24868109P 2009-10-05 2009-10-05
US61/248,681 2009-10-05
US28948309P 2009-12-23 2009-12-23
US61/289,483 2009-12-23
PCT/US2010/051329 WO2011044044A1 (en) 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015050464A Division JP2015163609A (ja) 2009-10-05 2015-03-13 心不全の予防又は処置の方法

Publications (2)

Publication Number Publication Date
JP2013506696A JP2013506696A (ja) 2013-02-28
JP2013506696A5 true JP2013506696A5 (https=) 2013-11-21

Family

ID=43823652

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012532388A Pending JP2013506696A (ja) 2009-10-05 2010-10-04 心不全の予防又は処置の方法
JP2015050464A Pending JP2015163609A (ja) 2009-10-05 2015-03-13 心不全の予防又は処置の方法
JP2016156631A Active JP6429835B2 (ja) 2009-10-05 2016-08-09 心不全の予防又は処置の方法
JP2018165223A Pending JP2018203764A (ja) 2009-10-05 2018-09-04 心不全の予防又は処置の方法
JP2020030241A Active JP7017762B2 (ja) 2009-10-05 2020-02-26 心不全の予防又は処置の方法
JP2022006917A Active JP7382607B2 (ja) 2009-10-05 2022-01-20 心不全の予防又は処置の方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015050464A Pending JP2015163609A (ja) 2009-10-05 2015-03-13 心不全の予防又は処置の方法
JP2016156631A Active JP6429835B2 (ja) 2009-10-05 2016-08-09 心不全の予防又は処置の方法
JP2018165223A Pending JP2018203764A (ja) 2009-10-05 2018-09-04 心不全の予防又は処置の方法
JP2020030241A Active JP7017762B2 (ja) 2009-10-05 2020-02-26 心不全の予防又は処置の方法
JP2022006917A Active JP7382607B2 (ja) 2009-10-05 2022-01-20 心不全の予防又は処置の方法

Country Status (7)

Country Link
US (7) US20110082084A1 (https=)
EP (5) EP2485749A4 (https=)
JP (6) JP2013506696A (https=)
CN (2) CN102711785A (https=)
CA (1) CA2776581C (https=)
HK (1) HK1217293A1 (https=)
WO (1) WO2011044044A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9306796B1 (en) 2008-03-18 2016-04-05 Mcafee, Inc. System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
EP3626252A1 (en) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2912386A1 (en) * 2013-05-14 2014-11-20 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricular remodeling
JP2016520130A (ja) * 2013-05-28 2016-07-11 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 心臓疾患における新規治療戦略としてのｂｅｔ阻害
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017861A1 (en) * 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2016004441A1 (en) * 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury
US10368774B2 (en) * 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CA3010599C (en) * 2016-01-06 2025-05-20 Stealth Biotherapeutics Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
WO2017151886A1 (en) * 2016-03-02 2017-09-08 Stealth Biotherapeutics Corp Methods and compositions for the treatment and prevention of pulmonary arterial hypertension
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US11865162B2 (en) 2016-07-01 2024-01-09 Marshall University Research Corporation Compositions and methods for treatment of uremic cardiomyopathy
CA3060985A1 (en) 2017-04-21 2018-10-25 Northeast Ohio Medical University Vasodilators for treatment of heart failure
WO2020118035A1 (en) * 2018-12-06 2020-06-11 Stealth Biotherapeutics Corp Methods and compositions for the treatment of sengers syndrome
CN112111003B (zh) * 2019-06-20 2022-02-11 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
US20230256047A1 (en) * 2020-06-17 2023-08-17 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN117384253A (zh) * 2023-08-28 2024-01-12 南京医科大学 一类肽及其衍生物和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4732898A (en) * 1986-04-29 1988-03-22 Warner-Lambert Company 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
JP2002512954A (ja) * 1998-04-24 2002-05-08 マイトコー ミトコンドリア関連疾患を処置するための化合物および方法
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7855900A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
IT1318370B1 (it) * 2000-12-21 2003-08-25 Tonino Bombardini Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7320959B2 (en) * 2001-10-01 2008-01-22 Vanderbilt University Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US7776925B2 (en) * 2002-03-06 2010-08-17 Duke University Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) * 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP3103467A1 (en) * 2008-02-07 2016-12-14 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative

Similar Documents

Publication Publication Date Title
JP2013506696A5 (https=)
JP2022046811A5 (https=)
Dingemanse et al. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist
Gradman et al. Renin inhibition in hypertension
RU2603050C2 (ru) Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
US20050037983A1 (en) Compositions and methods for the treatment of depression and other affective disorders
ME00479B (me) Lijek za profilaksu i tretman arterioskleroze i hipertenzije
US20250032466A1 (en) Methods of treating migraine
JP2007525440A6 (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
JP2013216708A (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP2016522196A5 (https=)
WO2021181368A1 (en) Methods of treating respiratory disease with deupirfenidone
AU2020201980A1 (en) Combination of FXR agonists
Passalia et al. Cardiovascular adverse events complicating the administration of rituximab: report of two cases
US20080153827A1 (en) Method for the Treatment or Prevention of Cardiac Hypertrophy
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
CN108815171B (zh) 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用
Geladari et al. A case of influenza type a myocarditis that presents with ST elevation MI, cardiogenic shock, acute renal failure, and rhabdomyolysis and with rapid recovery after treatment with oseltamivir and intra-aortic balloon pump support
Hamano et al. Effects of low-dose sacubitril/valsartan on different stages of cardiac hypertrophy in salt-loaded hypertensive rats
Oh et al. Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease
MacMahon et al. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40–5967), a novel calcium antagonist
Marques da Silva Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan
CN1298389C (zh) 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用
KR20220168172A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물